Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing
- Author:
Chaoyue LIANG
1
;
Zhuolin WU
;
Xiaohong GAN
;
Yuanbin LIU
;
You YOU
;
Chenxian LIU
;
Chengzhi ZHOU
;
Ying LIANG
;
Haiyun MO
;
Allen M CHEN
;
Jiexia ZHANG
Author Information
- Publication Type:Original Article
- Keywords: Non-small cell lung cancer; EGFR mutation; Sanger sequencing; ARMS
- MeSH: Adenocarcinoma/genetics; Adenocarcinoma/pathology; Aged; Aged, 80 and over; Animals; Base Sequence; Disease-Free Survival; Female; Humans; Lung Neoplasms/genetics; Lung Neoplasms/pathology; Male; Middle Aged; Mutation/genetics; Mutation Rate; Real-Time Polymerase Chain Reaction/methods; Receptor, Epidermal Growth Factor/genetics; Sequence Analysis, DNA/methods; Treatment Outcome
- From:Yonsei Medical Journal 2018;59(1):13-19
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This study aimed to identify potential epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer that went undetected by amplification refractory mutation system-Scorpion real-time PCR (ARMS-PCR). MATERIALS AND METHODS: A total of 200 specimens were obtained from the First Affiliated Hospital of Guangzhou Medical University from August 2014 to August 2015. In total, 100 ARMS-negative and 100 ARMS-positive specimens were evaluated for EGFR gene mutations by Sanger sequencing. The methodology and sensitivity of each method and the outcomes of EGFR-tyrosine kinase inhibitor (TKI) therapy were analyzed. RESULTS: Among the 100 ARMS-PCR-positive samples, 90 were positive by Sanger sequencing, while 10 cases were considered negative, because the mutation abundance was less than 10%. Among the 100 negative cases, three were positive for a rare EGFR mutation by Sanger sequencing. In the curative effect analysis of EGFR-TKIs, the progression-free survival (PFS) analysis based on ARMS and Sanger sequencing results showed no difference. However, the PFS of patients with a high abundance of EGFR mutation was 12.4 months [95% confidence interval (CI), 11.6−12.4 months], which was significantly higher than that of patients with a low abundance of mutations detected by Sanger sequencing (95% CI, 10.7−11.3 months) (p < 0.001). CONCLUSION: The ARMS method demonstrated higher sensitivity than Sanger sequencing, but was prone to missing mutations due to primer design. Sanger sequencing was able to detect rare EGFR mutations and deemed applicable for confirming EGFR status. A clinical trial evaluating the efficacy of EGFR-TKIs in patients with rare EGFR mutations is needed.
